版慢性乙型肝炎防治指南_培训课件.pptVIP

Current literature is largely consistent in suggesting that after starting a patient on antiviral treatment, the first assessment of the patient’s HBV DNA should ideally happen after 3 months of therapy. All patients with at least a 10 IU/mL or at least a 50 copies/mL decrease in viral load from baseline in the first 12 weeks of therapy are considered to be primary responders and should continue treatment. Patients with viral load decreases of less than 10 IU/mL or less than 50 copies/mL within the first 3 months of therapy are considered primary treatment failures, often due to poor adherenc